Age-related Macular Degeneration (AMD) is one of the prominent ocular diseases that lead to vision loss in older patients. With the gradual loss of photoreceptors and retinal pigment epithelial cells, the macula atrophies over time causing nonreversible central blindness. Steroid injections (such as Avastin & Vabysmo) are used today in clinics as the most common regimen for AMD symptom management. However, classical steroid injections do not always work, and have a high probability of procedure-related complications due to repeated monthly injections. Gene-manipulating and stem cell treatments offer an alternative, radical treatment path from the classic therapy to treat genetically triggered AMD with higher efficacy and specificity with far less frequency of administration compared to standard care. Six randomized phase 1/II clinical trials were selected from a pool of studies that investigated effectiveness, safety or both based on a strict search criteria that consisted of the terms and parameters of interest. A diagnostic table of the proper variables of interest was constructed and a meta-analysis assessing the odds ratio (OR) for therapy vs control arms was printed on a forest plot based on our selected data. This process utilized Microsoft Excel and R-Studio for all the statistical analyses performed. The meta-analysis revealed that Weiss et al. and Parker et al. were the two leading studies with the most significant weight of 33% and 24% respectively. The overall common effect from all the studies was found to be OR=3.28 (95% CI = 1.90-5.64). The common effect indicates that the odds of higher visual acuity fall within the study arm that received some sort of gene-related therapy in comparison to control. The overall study measure is statistically insignificant (p-value = 0.19 > 0.05), which was expected due to the small sample size recruited in all studies. The heterogeneity and Q-test values were all within the expected and accepted range considering the small sample size and therapy novelty as well. Light must be shed on gene and stem cell therapy by the scientific community as it has shown clinical evidence in treating many complicated diseases, including AMD. Moreover, such therapies can be utilized to target certain regions of the eye that are impacted by the illness, enabling a more specialized and efficient course of treatment.